Prinsloo Andrea, Pool Roger, Van Niekerk Chantal
Department of Haematology, Faculty of Health Sciences, University of Pretoria and Tshwane Academic Division of The National Health Laboratory Service, Pretoria, Gauteng, South Africa.
Department of Chemical Pathology, Faculty of Health Sciences, University of Pretoria and Tshwane Academic Division of The National Health Laboratory Service, Pretoria, Gauteng, South Africa.
Mol Clin Oncol. 2017 Sep;7(3):386-390. doi: 10.3892/mco.2017.1319. Epub 2017 Jul 13.
Micro-ribonucleic acids (miRNAs) are small functional non-coding RNAs that downregulate gene expression at the post-transcriptional level. Abnormal expression of specific miRNAs has been recorded in chronic lymphocytic leukaemia, other non-Hodgkin B-cell lymphomas, lung cancer and chronic myeloid leukaemia (CML). The aim of this study was to compare miRNA expression profiles among patients with newly diagnosed CML, those on established therapy with imatinib mesylate, and healthy individuals. The expression of 88 miRNAs was evaluated in a total of nine samples divided into three groups: Group 1 comprised three samples collected from newly diagnosed CML patients; group 2 consisted of three samples collected from patients on therapy; the remaining three samples were collected from healthy volunteers (control group). Total RNA was extracted from whole blood and reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) was performed on the LightCycler® 480 platform using Human Serum & Plasma miRNA PCR Arrays. In group 1, only SNORD44 was downregulated, while hsa-miR-372 and hsa-miR-375 were found to be significantly upregulated compared with the control group. By contrast, 49 miRNAs were significantly upregulated in group 2 compared with the control group. miRNAs hsa-miR-106b, hsa-miR-21, hsa-miR-221, hsa-miR-10a, hsa-miR-193a-5p and hsa-miR-30e were expressed in group 2. Therefore, miRNA expression profiles differed between the two patient groups.
微小核糖核酸(miRNA)是一类小的功能性非编码RNA,可在转录后水平下调基因表达。在慢性淋巴细胞白血病、其他非霍奇金B细胞淋巴瘤、肺癌和慢性粒细胞白血病(CML)中已记录到特定miRNA的异常表达。本研究的目的是比较新诊断的CML患者、接受甲磺酸伊马替尼既定治疗的患者和健康个体之间的miRNA表达谱。在总共九个样本中评估了88种miRNA的表达,这些样本分为三组:第1组包括从新诊断的CML患者中采集的三个样本;第2组由从接受治疗的患者中采集的三个样本组成;其余三个样本从健康志愿者中采集(对照组)。从全血中提取总RNA,并使用人血清和血浆miRNA PCR阵列在LightCycler® 480平台上进行逆转录定量聚合酶链反应(RT-qPCR)。在第1组中,只有SNORD44下调,而与对照组相比,发现hsa-miR-372和hsa-miR-375显著上调。相比之下,与对照组相比,第2组中有49种miRNA显著上调。miRNA hsa-miR-106b、hsa-miR-21、hsa-miR-221、hsa-miR-10a、hsa-miR-193a-5p和hsa-miR-30e在第2组中表达。因此,两个患者组之间的miRNA表达谱不同。